Safety & tolerability was never likely to be an issue given fda would only approve a much lower dosage compared to the MS trial 10 years ago so it's all about the EMA and the Phase IIb in 2020.
Best to just use Woodcock's own words on the preliminary data and safety profile though -
“Based on a preliminary review of the DMD trial data from the first six patients, the safety profile of ATL1102 appears satisfactory with no serious adverse events being reported during the trial so far."
Chart, page-591
-
- There are more pages in this discussion • 5,315 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |